Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
Journal
Liver International
Journal Volume
41
Journal Issue
6
Pages
1265-1277
Date Issued
2021
Author(s)
Chen C.-Y.
Huang C.-F.
Cheng P.-N.
Tseng K.-C.
Lo C.-C.
Kuo H.-T.
Huang Y.-H.
Tai C.-M.
Peng C.-Y.
Bair M.-J.
Chen C.-H.
Yeh M.-L.
Lin C.-L.
Lin C.-Y.
Lee P.-L.
Chong L.-W.
Hung C.-H.
Huang J.-F.
Yang C.-C.
Hu J.-T.
Lin C.-W.
Chen C.-T.
Wang C.-C.
Su W.-W.
Hsieh T.-Y.
Lin C.-L.
Tsai W.-L.
Lee T.-H.
Chen G.-Y.
Wang S.-J.
Chang C.-C.
Mo L.-R.
Yang S.-S.
Wu W.-C.
Huang C.-S.
Hsiung C.-K.
Kao C.-N.
Tsai P.-C.
Lee M.-H.
Dai C.-Y.
Chuang W.-L.
Lin H.-C.
Yu M.-L.
Abstract
Background/aims: Direct-acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)-infected patients. The real-world treatment outcome in Taiwanese patients on a nationwide basis is elusive. Methods: The Taiwan HCV Registry (TACR) programme is a nationwide registry platform including 48 study sites, which is organized and supervised by the Taiwan Association for the Study of the Liver. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA 12?weeks after end-of-treatment). Results: A total of 13?951 registered patients with SVR12 data available were analysed (mean age, 63.0?years; female, 55.9%; HCV genotype-1 [GT1], 57.9%; cirrhosis, 38.4%; preexisting hepatocellular carcinoma [HCC], 10.6%; and hepatitis B virus coinfection, 7.7%). The overall SVR12 rate was 98.3%, with 98.7%, 98.0%, 98.4% and 97.4% in treatment-na?ve noncirrhotic, treatment-na?ve cirrhotic, treatment-experienced noncirrhotic and treatment-experienced cirrhotic patients, respectively. The SVR12 rate was?>?95% across all subgroups except treatment-experienced cirrhotic patients who received sofosbuvir/ribavirin (88.7%), treatment-na?ve noncirrhotic patients (94.8%) and treatment-experienced cirrhotic (94.8%) patients who received daclatasvir/asunaprevir. The most important factor associated with treatment failure was DAA adherence?
SDGs
Other Subjects
antivirus agent; asunaprevir; daclatasvir; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; elbasvir plus grazoprevir; glecaprevir plus pibrentasvir; ledipasvir plus sofosbuvir; ribavirin; sofosbuvir; virus RNA; antivirus agent; sofosbuvir; adult; aged; Article; chronic hepatitis C; clinical feature; cohort analysis; coinfection; decompensated liver cirrhosis; drug efficacy; female; follow up; gastrointestinal disease; genotype; hepatitis B; human; infection; liver cell carcinoma; liver cirrhosis; liver disease; major clinical study; male; multicenter study; register; sustained virologic response; Taiwan; treatment failure; treatment outcome; treatment response; virus load; combination drug therapy; genetics; Hepacivirus; hepatitis C; liver cell carcinoma; liver tumor; middle aged; treatment failure; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Failure; Treatment Outcome
Publisher
John Wiley and Sons Inc
Type
journal article